Shanghai RAAS Blood Products (SHE:002252) agreed to fully acquire the Chinese subsidiary of Boehringer Ingelheim, Boehringer Ingelheim Biopharmaceuticals (China), according to a Shenzhen bourse filing on Thursday.
The consideration for the acquisition is based on a cash-free or debt-free principle and is subject to the purchase price adjustment.
Boehringer Ingelheim Biopharmaceuticals' registered capital amounts to $66 million.
The Chinese blood product manufacturer will takeover's shares rose 1% at the close.